ImmunityBio has surged over 200% YTD, yet I see little fundamental justification for its current $10B enterprise value. Click here to read why IBRX is a Sell.

A subtle but very important change is slowly happening behind the scenes of the UK's consumer telecoms industry, as broadband ...

In 2026, we expect scams to persist, especially as tools powered by artificial intelligence (AI) become more widely used. In this guide, we highlight several scam trends to watch out for and explain ...